Compare Mesoblast Limited (MESO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Redwire Corporation — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Redwire Corporation trades at $13.66 (market cap $3.28B). The key difference: Redwire Corporation is the larger of the two by market cap. Which is the better fit depends on your goals.
| MESO | RDW | |
|---|---|---|
Market Cap | $2.16B | $3.28B |
Sector | Technology | Technology |
52-Week High | $20.96 | $25.90 |
52-Week Low | $12.88 | $5.06 |
Enterprise Value | $2.17B | $2.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
RDW stock trades at $13.59, up 14.88% in the last 24 hours, reflecting strong momentum after Q2 2026 results. The company reported record revenue of $117.1 million and a growing backlog of $542.1 million, though it remains unprofitable with a net income margin of -57.26%. Technical indicators show a bullish trend, with the current price near the consensus target of $17.50, while analyst sentiment is overwhelmingly positive with 80% buy ratings.
The outlook hinges on execution of its space and defense contracts, but persistent losses and negative cash flows from operations pose significant risks. Upside potential exists if margin improvements materialize, yet investors face volatility from earnings misses and high burn rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
